Dr. John Cush RheumNow
3 years 4 months ago
Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development:
- Obinutuzumab
- Dapirolizumab
- Deucravacitinib
- Litifilimab
- Atacicept
- Telitacicept https://t.co/jMLlRZuK6e https://t.co/8K0dYLieAH
Dr. John Cush RheumNow
3 years 4 months ago
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors:
- RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz.
- avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV
RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.
Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?
Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).
Dr. John Cush RheumNow
3 years 4 months ago
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy
https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d
Dr. John Cush RheumNow
3 years 4 months ago
RheumThoughts: No is a complete sentence
Dr. Rachel Tate ( @uptoTate ) shares her POV.
https://t.co/0xzTobgmIQ https://t.co/YvEUMsqLyV
Dr. John Cush RheumNow
3 years 4 months ago
25 Great Women in Rheumatology
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized?
I'm sharing the responses.
https://t.co/N1zqs3TJuv https://t.co/LXDxnXUaG9
Dr. John Cush RheumNow
3 years 4 months ago
Denosumab Reduces Type II Diabetes Risk
The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis.
https://t.co/7SMjp258gX https://t.co/SAUmahwV9J
Dr. John Cush RheumNow
3 years 4 months ago
How Being a Patient Taught Me to Be a Better Doctor
Dr. Marcella Ferrada ( @maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician.
https://t.co/eUHzPTjRv8 https://t.co/rTIfyLwVLY
Dr. John Cush RheumNow
3 years 4 months ago
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu
Dr. John Cush RheumNow
3 years 4 months ago
RheumThoughts: No is a complete sentence
Dr. Rachel Tate ( @uptoTate ) shares her POV.
https://t.co/TGcFuGl4Lp https://t.co/N0bItVkHjM
Dr. John Cush RheumNow
3 years 4 months ago
25 Great Women in Rheumatology
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized?
I'm sharing the responses.
https://t.co/0d7SkgpcN5 https://t.co/nQVfs5oMFL
Dr. John Cush RheumNow
3 years 4 months ago
Narrative Medicine
Dr. Aviya Lanis shares with us how narrative medicine helped her become a more engaging doctor.
https://t.co/YJdsa50FBF https://t.co/7D3DiBnqaK
Dr. John Cush RheumNow
3 years 4 months ago
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies 4661 pts. Corticosteroids reduced mortality in more severe CAP (RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/dj7zABqQ3r https://t.co/Mb4g7ICdX9
Dr. John Cush RheumNow
3 years 4 months ago
Metanalysis of IV NA Thiosulphate for Calciphylaxis in CKD shows NO improvement in skin lesion (RR 1.23; 0.85-1.78) or survival (HR 0.82; 0.57-1.18); based on 19 studies and 422 pts https://t.co/0uyHhWJpFJ https://t.co/dkRgRjh2cH
